Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “overweight” rating reissued by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Friday.

Several other equities analysts have also recently commented on the company. Goldman Sachs Group Inc. restated a “buy” rating and set a $158.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, November 10th. Wedbush restated a “neutral” rating and set a $135.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, November 10th. Leerink Swann restated a “buy” rating and set a $211.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, November 7th. Credit Suisse Group AG restated a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, November 7th. Finally, Piper Jaffray Cos. set a $176.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $173.36.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 118.89 on Friday. The company has a market cap of $26.65 billion, a PE ratio of 72.49 and a beta of 1.45. The stock’s 50 day moving average price is $123.55 and its 200-day moving average price is $130.23. Alexion Pharmaceuticals has a 52 week low of $110.56 and a 52 week high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.19. The company earned $799 million during the quarter, compared to analysts’ expectations of $787.07 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.16 earnings per share. Analysts expect that Alexion Pharmaceuticals will post $4.64 EPS for the current year.

In related news, Director Leonard Bell sold 1,300 shares of the company’s stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $135.28, for a total value of $175,864.00. Following the sale, the director now owns 406,589 shares in the company, valued at approximately $55,003,359.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Edward Miller sold 367 shares of the company’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $128.32, for a total value of $47,093.44. Following the completion of the sale, the senior vice president now owns 16,519 shares in the company, valued at approximately $2,119,718.08. The disclosure for this sale can be found here. 4.41% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Zurich Insurance Group Ltd FI increased its stake in Alexion Pharmaceuticals by 55.2% in the first quarter. Zurich Insurance Group Ltd FI now owns 34,580 shares of the biopharmaceutical company’s stock valued at $4,814,000 after buying an additional 12,298 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock valued at $128,153,000 after buying an additional 35,267 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Alexion Pharmaceuticals by 19.8% in the first quarter. Envestnet Asset Management Inc. now owns 28,327 shares of the biopharmaceutical company’s stock valued at $3,944,000 after buying an additional 4,688 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Alexion Pharmaceuticals during the first quarter valued at approximately $418,000. Finally, Arizona State Retirement System increased its stake in shares of Alexion Pharmaceuticals by 0.8% in the first quarter. Arizona State Retirement System now owns 61,100 shares of the biopharmaceutical company’s stock valued at $8,506,000 after buying an additional 500 shares in the last quarter. Institutional investors own 97.33% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.